Un antibiotic utilizat pentru pneumonie și infecții urinare, asociat cu un risc mai mare de deces

A recent analysis published in JAMA Network Open raises concerns about the safety of cefepime, a commonly used antibiotic. Researchers reviewed data from 110 randomized clinical trials involving over 22,000 patients. The study found a higher mortality rate associated with cefepime compared to other beta-lactam antibiotics, particularly in adults and patients with febrile neutropenia. However, the results do not establish a direct causal link between cefepime and deaths. The authors suggest that dosing issues may contribute to the observed risks. They emphasize the need for careful reevaluation of cefepime's use and further research on optimal dosing. The study has limitations, including variations in patient categories and treatment protocols across different studies.